Ningbo NewBay In-Licenses Novel Genentech Oncology Candidate

Ningbo NewBay Medical Technology in-licensed greater China rights to a novel small molecule Pan-PIM inhibitor from Genentech, a Roche company. GDC-0570 showed efficacy against multiple myeloma and prostate cancer in preclinical tests, according to the company. The PIM kinases regulate cell metabolism, and GDC-0570 is a potential first-in-class drug candidate. Ningbo NewBay is a subsidiary of Ningbo Tai Kang Medical Technology. NewBay and Tai Kang own greater China rights for two EP4 antagonists from AskAt and global rights for a c-KIT inhibitor from AstraZeneca. More details.... Stock Symbols: (SIX: ROG) (NYSE: AZN) Share this with colleagues: // //